JPH06292580A - レチノイドｘレセプターのアゴニストおよびアンタゴニストに対する作用機作に基づくスクリーニング - Google Patents

レチノイドｘレセプターのアゴニストおよびアンタゴニストに対する作用機作に基づくスクリーニング

Info

Publication number
JPH06292580A
JPH06292580A JP5349809A JP34980993A JPH06292580A JP H06292580 A JPH06292580 A JP H06292580A JP 5349809 A JP5349809 A JP 5349809A JP 34980993 A JP34980993 A JP 34980993A JP H06292580 A JPH06292580 A JP H06292580A
Authority
JP
Japan
Prior art keywords
rxrα
site
yeast
receptor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5349809A
Other languages
English (en)
Japanese (ja)
Inventor
Paul Mak
ポール・マク
Sotirios K Karathanasis
ソテイリオス・ケイ・カラサナシス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of JPH06292580A publication Critical patent/JPH06292580A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01012—Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) (1.2.1.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01013—Glyceraldehyde-3-phosphate dehydrogenase (NADP+) (phosphorylating) (1.2.1.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
    • G01N2333/395—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts from Saccharomyces
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP5349809A 1992-12-31 1993-12-29 レチノイドｘレセプターのアゴニストおよびアンタゴニストに対する作用機作に基づくスクリーニング Pending JPH06292580A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/999,071 US5691196A (en) 1992-12-31 1992-12-31 Recombinant nucleic acid containing a response element
US999071 1992-12-31

Publications (1)

Publication Number Publication Date
JPH06292580A true JPH06292580A (ja) 1994-10-21

Family

ID=25545860

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5349809A Pending JPH06292580A (ja) 1992-12-31 1993-12-29 レチノイドｘレセプターのアゴニストおよびアンタゴニストに対する作用機作に基づくスクリーニング

Country Status (6)

Country Link
US (4) US5691196A (enExample)
EP (1) EP0608532A3 (enExample)
JP (1) JPH06292580A (enExample)
KR (1) KR940014779A (enExample)
CA (1) CA2112527A1 (enExample)
TW (1) TW284787B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009232697A (ja) * 2008-03-26 2009-10-15 Nagase & Co Ltd 形質転換酵母、それを用いた分析方法および分析キット

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU703124B2 (en) 1995-03-03 1999-03-18 Syngenta Participations Ag Control of gene expression in plants by receptor mediated transactivation in the presence of a chemical ligand
FR2735370B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Procede pour identifier des composes agonistes des recepteurs rxrs
CA2231833A1 (en) * 1995-09-20 1997-03-27 Novo Nordisk A/S New furyl-pyridone compounds, useful as fungicides and obtained from the fungus cladobotryum
EP0859851A1 (en) 1995-10-10 1998-08-26 Novartis AG Juvenile hormone or one of its agonists as a chemical ligand to control gene expression in plants by receptor mediated transactivation
EP1143953A3 (en) * 1998-11-20 2002-02-06 Genentech, Inc. Method of inhibiting angiogenesis
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
WO2000043787A1 (en) * 1999-01-26 2000-07-27 Du Pont Pharmaceuticals Company Electrophoretic assays to assess conformational changes of integrins induced by ligand binding
JP2003508042A (ja) * 1999-09-01 2003-03-04 アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル・（イ・エヌ・エス・ウ・エール・エム） インビトロ転写系および用途
WO2001051045A2 (en) * 2000-01-13 2001-07-19 Tularik Inc. Modulators of the constitutive adrostane receptor (car): screening and treatment of hypercholesterolemia
US6432427B1 (en) * 2000-06-30 2002-08-13 Unilever Hope & Personal Care Usa, Division Of Conopco, Inc. Cosmetic compositions containing substituted sulfonamide derivatives
CA2439263C (en) * 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
US20020193403A1 (en) * 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US20030155328A1 (en) * 2002-02-15 2003-08-21 Huth Mark C. Laser micromachining and methods and systems of same
US20030170724A1 (en) * 2002-03-08 2003-09-11 Anderson David C. Methods of identifying target polypeptides
KR100492514B1 (ko) * 2002-05-03 2005-06-03 학교법인 포항공과대학교 레티노산에 의해 발현이 조절되는 재조합 리포터 유전자를가지는 형질전환 세포주 및 이를 이용한 레티노산유사물질 및 저해물질의 생물학적 검색방법
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
JP2010506955A (ja) 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
EP2858636B1 (en) * 2012-06-07 2018-09-05 Childrens Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
KR20160113302A (ko) 2014-02-18 2016-09-28 칠드런＇스 하스피틀 로스 앤젤레스 호중구감소증을 치료하기 위한 조성물 및 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826062D0 (en) * 1988-11-07 1988-12-14 Raychem Sa Nv Splice case for optical fibre cable
AU637446B2 (en) * 1990-01-16 1993-05-27 Baylor College Of Medicine Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vectors
US5552271A (en) * 1992-06-16 1996-09-03 La Jolla Cancer Research Foundation RXR homodimer formation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009232697A (ja) * 2008-03-26 2009-10-15 Nagase & Co Ltd 形質転換酵母、それを用いた分析方法および分析キット

Also Published As

Publication number Publication date
CA2112527A1 (en) 1994-07-01
TW284787B (enExample) 1996-09-01
EP0608532A2 (en) 1994-08-03
US5700650A (en) 1997-12-23
US5700682A (en) 1997-12-23
EP0608532A3 (en) 1995-11-15
US5714595A (en) 1998-02-03
US5691196A (en) 1997-11-25
KR940014779A (ko) 1994-07-19

Similar Documents

Publication Publication Date Title
JPH06292580A (ja) レチノイドｘレセプターのアゴニストおよびアンタゴニストに対する作用機作に基づくスクリーニング
Miyata et al. The Orphan Nuclear Hormone Receptor LXRα Interacts with the Peroxisome Proliferator-activated Receptor and Inhibits Peroxisome Proliferator Signaling (∗)
Liden et al. A new function for the C-terminal zinc finger of the glucocorticoid receptor: repression of RelA transactivation
Kurokawa et al. Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding
Hassan et al. Function and selectivity of bromodomains in anchoring chromatin-modifying complexes to promoter nucleosomes
McDONNELL et al. In situ distinction between steroid receptor binding and transactivation at a target gene
Widom et al. Repression by ARP-1 sensitizes apolipoprotein A1 gene responsiveness to RXRα and retinoic acid
Cheung et al. Dissociation of eIF1 from the 40S ribosomal subunit is a key step in start codon selection in vivo
Martin et al. The human 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase type 2 promoter is a novel target for the immediate early orphan nuclear receptor Nur77 in steroidogenic cells
Lemon et al. Selective effects of ligands on vitamin D3 receptor-and retinoid X receptor-mediated gene activation in vivo
Jin et al. Transcriptional activation and dimerization functions in the human vitamin D receptor.
JP2000500227A (ja) 基本転写機構のレチノイドｘレセプターおよび成分
Burbach et al. Repression of estrogen-dependent stimulation of the oxytocin gene by chicken ovalbumin upstream promoter transcription factor I.
US5747661A (en) Retinoid-inducible response elements
EP0743520A2 (en) Novel uses for GAL4-receptor constructs
Brasier et al. Synergistic enhansons located within an acute phase responsive enhancer modulate glucocorticoid induction of angiotensinogen gene transcription
WO1996021726A9 (en) Identification of a distinct retinoid-responsive pathway and uses therefor
Harding et al. Retinoic acid activation and thyroid hormone repression of the human alcohol dehydrogenase gene ADH3.
George et al. Dynamic access of the glucocorticoid receptor to response elements in chromatin
US6893830B1 (en) Method of screening oxysterol activation of LXRα
Marcus et al. Identification of COUP-TFII as a peroxisome proliferator response element binding factor using genetic selection in yeast: COUP-TFII activates transcription in yeast but anatagonizes PPAR signaling in mammalian cells
Uppaluri et al. Genetic dissection of thyroid hormone receptor β: identification of mutations that separate hormone binding and transcriptional activation
Hatzivassiliou et al. Ultraspiracle, a Drosophila retinoic X receptor α homologue, can mobilize the human thyroid hormone receptor to transactivate a human promoter
Gurevich et al. Liganded RARα and RARγ interact with but are repressed by TNIP1
Mu et al. TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC‐3